Researchers at Dana-Farber Cancer Institute have tested an idea born at the Salk Institute in actual patients: that switching on the vitamin D receptor can loosen the dense, protective tissue that surrounds pancreatic tumors and shields them from treatment. The small clinical trial, published May 25, 2026, in Nature Cancer, enrolled patients with previously untreated metastatic pancreatic cancer and gave them standard chemotherapy either alone or combined with paricalcitol, a vitamin D analog already approved by the FDA for other conditions.
Given orally or intravenously, paricalcitol proved safe alongside chemotherapy and reduced activation of fibroblasts in the tumor microenvironment. Those fibroblasts are the cells that build the fibrotic barrier around pancreatic tumors, one reason the disease resists drugs that work elsewhere in the body. Seeing that effect in patients confirms what the Salk preclinical work had predicted.
The trial was not designed to measure whether the combination actually treats the cancer better, but the researchers reported some encouraging signals anyway: improved chemotherapy responses and higher progression-free survival at one year among those who got paricalcitol. Patients whose tumors expressed high levels of the vitamin D receptor and who received the drug had the longest overall survival, hinting that receptor expression might one day help identify who benefits.
As the researchers framed it, the strategy works by engaging the body's own system for dampening fibrotic and inflammatory responses so that other therapies can reach their target. That logic - using an existing, approved drug to change the terrain around a tumor rather than attacking the tumor directly - is what makes the result worth watching. A trial this small, and one not powered to test efficacy, cannot settle whether the approach extends lives; larger studies designed around survival endpoints would be the next step.